Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
Public ClinicalTrials.gov record NCT00086671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans done periodically throughout the study.
Study identification
- NCT ID
- NCT00086671
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 215 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2004
- Primary completion
- Oct 31, 2006
- Completion
- Oct 31, 2006
- Last update posted
- Jan 3, 2013
2004 – 2006
United States locations
- U.S. sites
- 27
- U.S. states
- 20
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 107 | Phoenix | Arizona | 85013 | — |
| Site Reference ID/Investigator# 163 | Sun City | Arizona | 85351 | — |
| Site Reference ID/Investigator# 156 | Little Rock | Arkansas | 72205 | — |
| Site Reference ID/Investigator# 154 | Irvine | California | 92618 | — |
| Site Reference ID/Investigator# 161 | Laguna Hills | California | 92653 | — |
| Site Reference ID/Investigator# 84 | Sacramento | California | 95817 | — |
| Site Reference ID/Investigator# 119 | Boulder | Colorado | 80304 | — |
| Site Reference ID/Investigator# 111 | Miami | Florida | 33136 | — |
| Site Reference ID/Investigator# 151 | Tallahassee | Florida | 32308 | — |
| Site Reference ID/Investigator# 108 | Atlanta | Georgia | 30309 | — |
| Site Reference ID/Investigator# 109 | Atlanta | Georgia | 30327 | — |
| Site Reference ID/Investigator# 105 | Northbrook | Illinois | 60062 | — |
| Site Reference ID/Investigator# 152 | Indianapolis | Indiana | 46260 | — |
| Site Reference ID/Investigator# 258 | Lenexa | Kansas | 66214 | — |
| Site Reference ID/Investigator# 261 | Lexington | Kentucky | 40503 | — |
| Site Reference ID/Investigator# 116 | Detroit | Michigan | 48201 | — |
| Site Reference ID/Investigator# 158 | Traverse City | Michigan | 49684 | — |
| Site Reference ID/Investigator# 124 | St Louis | Missouri | 63110 | — |
| Site Reference ID/Investigator# 259 | Henderson | Nevada | 89052 | — |
| Site Reference ID/Investigator# 153 | Lebanon | New Hampshire | 03766 | — |
| Site Reference ID/Investigator# 110 | Albany | New York | 12205 | — |
| Site Reference ID/Investigator# 117 | Charlotte | North Carolina | 28207 | — |
| Site Reference ID/Investigator# 113 | Columbus | Ohio | 43210 | — |
| Site Reference ID/Investigator# 157 | Dayton | Ohio | 45409 | — |
| Site Reference ID/Investigator# 114 | Allentown | Pennsylvania | 18103 | — |
| Site Reference ID/Investigator# 128 | Houston | Texas | 77030 | — |
| Site Reference ID/Investigator# 155 | Bennington | Vermont | 05201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00086671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 3, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00086671 live on ClinicalTrials.gov.